The Development of STING Agonists and Emerging Results as a Cancer Immunotherapy.
Jacobi B HinesAlec J KacewRandy F SweisPublished in: Current oncology reports (2023)
Preclinical data has shown that the addition of a STING agonist enhances the effect of current treatments such as immune checkpoint inhibitor antibodies and radiation therapy. Early phase trials have demonstrated modest efficacy of STING agonists and revealed new mechanistic and technical challenges. STING agonists are a new class of agents that activate the immune response to improve tumor control. A wide range of preclinical experiments, translational data, and ongoing clinical trials support the therapeutic use of STING agonists in patients. Trials to determine optimal drug combinations and novel delivery mechanisms are continuing in development.
Keyphrases
- radiation therapy
- clinical trial
- immune response
- end stage renal disease
- electronic health record
- newly diagnosed
- big data
- cell therapy
- peritoneal dialysis
- stem cells
- prognostic factors
- randomized controlled trial
- single cell
- patient reported outcomes
- mesenchymal stem cells
- machine learning
- patient reported
- open label
- bone marrow
- rectal cancer
- phase ii